Table 6.
Cell type | Inoculation technique | Administration | Ref. |
---|---|---|---|
human neuroblastoma (IMR-32) | serum-free medium and matrigel | topical | [108] |
human epidermoid carcinoma, human sarcoma, human embryonal rhabdomyosarcoma | explanted | subcutaneous | [16] |
rat sarcoma | explanted | into the CAM | [92] |
human epidermoid carcinoma (HEp-3) | suspension | topical | [109] |
estrogen receptor negative (MDAMB231) and positive (MCF-7) breast adenocarcinoma | [109] | ||
androgen receptor negative (PC3) and positive (LNCaP) prostate adenocarcinoma | [109] | ||
human fibrosarcoma (HT-1080) | [109,93] [110] |
||
human ovarian carcinoma (OVCAR-3, SKOV-3 and OV-90) | [111] | ||
human embryo fibroblasts (HEF) | [109] | ||
human colon carcinoma metastatic (SW620) and non-metastatic (SW480) | suspension in serum-free medium | i.v. | [93] |
rat C6 glioma and 10AS pancreatic carcinoma | suspension in medium | topical | [83] |
human Burkitt’s lymphoma (BL) | matrigel | [112] |